MedPacto, a subsidiary of TheragenEtex, has passed the technology assessment required for listing on KOSDAQ and is promoting special listing for technology.
In recently conducted technology assessment, MedPacto received “A” grade from both expert evaluation institutes designated by Korea Exchange, eCredible and Korea Enterprise Data.
MedPacto, based on this success, has established a new goal to rapidly start preparations for preliminary examination for listing within few days and enter KOSDAQ market in this year, if possible.
MedPacto, having spun off from TheragenEtex in 2013, is a new company specializing in anticancer drug development. The headquarter and research lab are located in Seocho-dong, Seoul.